Next, to validate whether the downregulated genes, such as MAF, GATA6, and DAB2, are affected by epigenetic dysregulation, we treated ovarian cancer cell lines with a pan-HDAC inhibitor, TSA, which mechanistically augments transcriptionally active histone modification. This evidence concerns the gene HDAC9 and ovarian cancer.